Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Beijing Municipal Health Commission | OTHER_GOV |
Not provided
Not provided
Not provided
Through a randomized controlled trial (RCT) design, this study aiming to evaluated the efficacy and safety of rituximab lymph node injection combined with pulmonary vascular interventional therapy in treating fibrosing mediastinal pulmonary hypertension (FM-PH).Eligible participants were randomly assigned to either the combined treatment group, receiving both pulmonary vascular intervention and rituximab lymph node injection, or the interventional-only group, which received pulmonary vascular intervention alone. At 3, 6, and 12 months post-treatment, the efficacy was assessed based on symptom improvement, hemodynamic changes, lesion volume reduction, etc. Safety was mainly evaluated by comparing adverse event incidence between the two groups.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Combined treatment group | Experimental | Participants assigned to this group will receive both pulmonary vascular intervention and rituximab lymph node injection. |
|
| Interventional-only group | Active Comparator | Participants assigned to this group will receive pulmonary vascular intervention alone. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention | Procedure | Based on the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed vessels. During the treatment cycle, one lymph node drug injection is administered: 50mg of rituximab is dissolved in 15ml of 5% glucose solution and injected at multiple sites into the identified enlarged mediastinal lymph nodes under ultrasound-guided bronchoscopy. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in the Six Minutes Walk Distance at 12 Months. | Conduct 6-minute walk test to measure the 6-minute walk distance, and compare the walking distances at baseline and 12 months after treatment. | From enrollment to the end of treatment at 12 months |
| The incidence of treatment-related serious adverse events (SAE) | The incidence of treatment-related serious adverse events is measured by tracking and documenting any SAEs that occur during the treatment period, as well as through follow-up assessments. Each event is evaluated for severity and causality, and the incidence is calculated by dividing the number of patients who experience at least one treatment-related SAE by the total number of treated patients. | During the one-year follow-up period after treatment completion |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in the World Health Organization Functional Classification of Pulmonary Hypertension at 3, 6 and 12 months. | Change from Baseline in the World Health Organization Functional Classification of Pulmonary Hypertension (WHO-FC) which assessed based on clinical symptoms and signs at baseline and the end of treatment at 3, 6 and 12 months. The WHO-FC system consists of four levels: I, II, III, and IV. Higher levels indicate progressively more severe conditions. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Juanni Gong, Doctor of Medicine | Contact | 15801511482 | juannigong2018@126.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing Chaoyang Hospital, Capital Medical University | Recruiting | Beijing | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39397011 | Background | Jia M, Su H, Jiang K, Wang A, Guo Z, Zhu H, Zhang F, Sun X, Shi Y, Pan X, Cao Y. Incidence and predictors of in-stent restenosis following intervention for pulmonary vein stenosis due to fibrosing mediastinitis. Orphanet J Rare Dis. 2024 Oct 14;19(1):379. doi: 10.1186/s13023-024-03391-8. | |
| 39106522 | Background |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C536136 | Mediastinal Fibrosis |
| D006976 | Hypertension, Pulmonary |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Pulmonary Vascular Interventional Therapy | Procedure | According to the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed pulmonary vessels. |
|
| From enrollment to the end of treatment at 3, 6 and 12 months. |
| Change from Baseline in the mean pulmonary artery pressure (mPAP) at 3 and 12 Months. | The mean pulmonary artery pressure (mPAP) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months. | From enrollment to the end of treatment at 3 and12 months |
| Change from Baseline in the Cardiac Index (CI) at 3 and 12 Months. | The Cardiac Index (CI) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months. | From enrollment to the end of treatment at 3 and12 months |
| Change from Baseline in the Pulmonary Vascular Resistance (PVR) at 3 and 12 Months. | The Pulmonary Vascular Resistance (PVR) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months. | From enrollment to the end of treatment at 3 and12 months |
| Change from Baseline in the forced vital capacity (FVC) at 3, 6 and 12 Months. | Pulmonary function tests was performed, including the forced vital capacity (FVC), to evaluated pulmonary function at baseline and the end of treatment at 3, 6 and 12 Months. | From enrollment to the end of treatment at 3, 6 and 12 months |
| Change from Baseline in the forced vital capacity of predicted (FVC%pred) at 3, 6 and 12 Months. | Pulmonary function tests was performed, including the forced vital capacity of predicted (FVC%pred), to evaluated pulmonary function at baseline and the end of treatment at 3, 6 and 12 Months. | From enrollment to the end of treatment at 3, 6 and 12 months |
| Change from Baseline in the forced expiratory volume in 1 second (FEV1) at 3, 6 and 12 Months. | Pulmonary function tests was performed, including the forced expiratory volume in 1 second (FEV1), to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months. | From enrollment to the end of treatment at 3, 6 and 12 months |
| Change from Baseline in the forced expiratory volume in 1 second of predicted (FEV1%pred) at 3, 6 and 12 Months. | Pulmonary function tests was performed, including the forced expiratory volume in 1 second of predicted (FEV1%pred), to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months. | From enrollment to the end of treatment at 3, 6 and 12 months |
| Change from Baseline in the FEV1/FVC ratio at 3, 6 and 12 Months. | Pulmonary function tests was performed, including the FEV1/FVC ratio, to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months. | From enrollment to the end of treatment at 3, 6 and 12 months |
| Change of the BNP/NT-Pro BNP from baseline to the end of treatment at 3, 6 and 12 months. | The BNP/NT-Pro BNP will be measured at baseline the end of treatment at 3, 6 and 12 months to evaluate the condition of heart failure. | From enrollment to the end of treatment at 3, 6 and 12 months. |
| The restenosis rate of blood vessels after interventional therapy at the end of treatment at 3 and 12 months | Restenosis following interventional therapy was monitored at the end of treatment at 3 and 12 months, with restenosis defined as a blood vessel diameter reduction of more than 50% from the original size, or when the pressure gradient (Pd) at the site of vascular stenosis increases by 5 mmHg or more compared to the last measurement. | From enrollment to the end of treatment at 3 and 12 months. |
| Change of the mediastinal lesion volume from baseline to 3 and 12 months after the end of treatment. | The mediastinal lesion volume will be measured at baseline and 3, 12 months after the end of treatment using CTPA or PET-CT imaging. The volume is represented by the maximum transverse diameter of the cross-section of the lesion site. | From enrollment to the end of treatment at 3 and12 months. |
| Change from baseline of the quality-of-life score at 3, 6 and 12 months after the end of treatment. | Quality of life was assessed using the 36-Item Short-Form Health Survey (SF-36) at baseline and 3, 6 and 12 months after the end of treatment. The SF-36 scoring scale consists of 8 dimensions, which can be summarized as physical health and mental health. The score range of each dimension is 0 to 100 points. The higher the score, the better the health condition. | From enrollment to the end of treatment at 3, 6 and 12 months |
| Number of participants with complications of bronchoscopy and pulmonary intervention. | Measure the probability of complications occurring during or after therapeutic operations. Complications of pulmonary vascular intervention include pulmonary vascular injury, arrhythmia, reperfusion pulmonary edema, etc; Complications of bronchoscopy include pneumothorax, massive hemoptysis, infection, etc. | Immediately or in the short term after treatment, and within 12 months after treatment |
| Varghese C, Johnson GB, Eiken PW, Edell ES, Specks U, Larson NB, Peikert T. A Retrospective Evaluation of the Treatment Effects of Rituximab in Patients with Progressive and Symptomatic Fibrosing Mediastinitis. Ann Am Thorac Soc. 2024 Nov;21(11):1533-1541. doi: 10.1513/AnnalsATS.202405-533OC. |
| D002318 |
| Cardiovascular Diseases |